Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

被引：1
|
作者：
van der Wekken, Anthonie J. [1 ]
Kok, Klaas [2 ,3 ]
Groen, Harry J. M. [1 ]
机构：
[1] Univ Groningen, Dept Pulm Dis, Groningen, Netherlands
[2] Univ Groningen, Dept Genet, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
CRIZOTINIB; RESISTANCE; INHIBITOR;
D O I：
10.21037/jtd.2018.06.45
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S2130 / S2132
页数：3
相关论文
共 50 条
  • [31] Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients
    Clave, S.
    Salido, M.
    Gibert, J.
    Hardy-Werbin, M.
    Weingartner, E.
    Hernandez, J.
    Nichol, D.
    Rocha, P.
    Riera, X.
    Blanco, R.
    Bosch-Barrera, J.
    Taus, A.
    Pijuan, L.
    Bellosillo, B.
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S508 - S509
  • [32] Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Numata, Takeshi
    Endo, Takeo
    Yamamoto, Yusuke
    Shimizu, Kei
    Yamada, Hideyasu
    Hayashihara, Kenji
    Okauchi, Shinichiro
    Satoh, Hiroaki
    Yamada, Yutaka
    Tamura, Tomohiro
    Saito, Kazuto
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Watanabe, Hiroko
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Funayama, Yasunori
    Hayashi, Shigen
    Nakamura, Hiroyuki
    Yamashita, Takaaki
    IN VIVO, 2020, 34 (04): : 2001 - 2007
  • [33] HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN SECOND LINE WITH ALECTINIB
    Greillier, L.
    Tuzelet, V
    Cadranel, J.
    Thiberville, L.
    Chouaid, C.
    Girard, N.
    Cortot, A. B.
    Felicio, H.
    Weber, V
    Pau, D.
    VALUE IN HEALTH, 2020, 23 : S423 - S423
  • [34] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Pan, Yue
    Deng, Chao
    Qiu, Zhenhua
    Cao, Chenghui
    Wu, Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [36] Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
    Awad, Mark
    Mastini, Cristina
    Patino, Rafael
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy
    Adeni, Anika
    Lydon, Christine
    Janne, Pasi
    Chiarle, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1163
  • [37] Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 255 - 268
  • [38] Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib
    Nishino, Mizuki
    Wei, Zihan
    Mazzola, Emanuele
    Hino, Takuya
    Tseng, Shu-Chi
    Sanchez, Michelle E.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [39] Clinical experience in patients with advanced ALK-Rearranged non-small cell lung cancer and brain metastases in China
    Han, Y.
    Ren, K.
    Zhang, H.
    Sun, L.
    Ren, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
    Blasco, Rafael B.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
12345